AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of human growth hormone, specifically amino acids 177-191 of the GH molecule with a tyrosine addition at the C-terminus. It was developed to isolate the lipolytic (fat-burning) properties of growth hormone from its growth-promoting and diabetogenic effects. Unlike full-length GH or even the unmodified HGH fragment 176-191, AOD-9604 does not affect IGF-1 levels, does not impair insulin sensitivity, and does not promote the growth of tissues other than its targeted effect on adipocytes.

The mechanism is direct stimulation of lipolysis and inhibition of lipogenesis in adipose tissue, mediated through the beta-3 adrenergic receptor pathway. AOD-9604 increases fat oxidation — the rate at which stored triglycerides are broken down and used as fuel — without the catabolic effects on muscle tissue that caloric restriction alone can produce.

This protocol is designed for individuals whose primary goal is fat loss with preservation of lean mass, particularly those who have plateaued with diet and exercise alone or who want to accelerate body composition changes without the systemic effects of full GH therapy.

Dose selection

AOD-9604 dosing follows a straightforward range without the complex titration required by GLP-1 agonists or growth hormone secretagogues.

Starting dose: 300 mcg per day. This is the minimum effective dose for most individuals and the appropriate starting point to assess tolerance. Most users experience no side effects at this dose, but starting here allows identification of the rare individual who is sensitive to any GH-fragment compound.

Standard dose: 500 mcg per day. This is the most commonly used dose in practice and the dose most frequently referenced in the clinical literature. The majority of users will settle at this dose for the duration of their cycle.

Upper dose: 600 mcg per day. Some practitioners use this dose for individuals with higher body fat percentages (above 30%) or those who have demonstrated good tolerance at 500 mcg without adequate response after 4 weeks. There is limited evidence that doses above 600 mcg provide additional benefit, and the cost-to-benefit ratio deteriorates at higher doses.

Dose escalation approach: Begin at 300 mcg daily for the first 5-7 days. If well tolerated, increase to 500 mcg daily. Remain at 500 mcg for at least 3-4 weeks before considering an increase to 600 mcg. Most users will not need to go beyond 500 mcg.

Some protocols split the daily dose into two administrations (e.g., 250 mcg in the morning and 250 mcg before bed). The rationale is to provide two windows of enhanced lipolysis rather than one. However, compliance is better with a single daily injection, and there is no controlled evidence demonstrating superiority of split dosing over a single daily dose.

Route and administration

Route: Subcutaneous injection only. AOD-9604 is a peptide and is destroyed by gastric acid if taken orally (despite some marketing of oral formulations, bioavailability via the oral route is negligible for meaningful fat loss effects).

Injection site: Abdominal subcutaneous fat, rotating between left and right sides of the navel, approximately 2-3 inches from the umbilicus. The abdomen provides consistent subcutaneous absorption. Some practitioners recommend injecting directly into the area of greatest fat deposit to exploit local effects, though systemic circulation is the primary distribution mechanism.

Timing — the fasted state requirement: AOD-9604 must be administered in a fasted state. This is not optional. The peptide's lipolytic mechanism requires a low-insulin environment to function effectively. Elevated insulin suppresses lipolysis and directly counteracts AOD-9604's mechanism of action.

Practical timing protocol:

Inject immediately upon waking, before any food or caloric beverage
Wait a minimum of 20-30 minutes before eating (60 minutes is preferable)
Water, black coffee, and plain tea (no sugar, no cream, no milk) are acceptable during the fasting window
If using a split-dose protocol, the second injection should be administered at least 3 hours after the last meal, ideally before bed

Reconstitution: AOD-9604 typically arrives as a lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water. Add the bacteriostatic water slowly along the side of the vial — do not inject directly onto the powder cake or shake the vial. Gently swirl until fully dissolved. Store reconstituted AOD-9604 in the refrigerator (2-8 degrees Celsius) and use within 4-6 weeks.

Cycle structure

AOD-9604 is not used indefinitely. Cycling prevents potential receptor desensitization and aligns with the practical reality that fat loss is a time-limited goal — once target body composition is reached, the focus shifts to maintenance through diet and lifestyle.

Standard cycle: 8-12 weeks of daily administration.

8-week cycle: Appropriate for individuals with moderate fat loss goals (5-10 lbs), those combining with other interventions that independently drive fat loss, or those using AOD-9604 as a "finishing" compound to address stubborn fat deposits after significant weight loss through other means.

12-week cycle: Appropriate for individuals with more substantial fat loss goals (10-20 lbs), those using AOD-9604 as a primary peptide intervention, or those with higher starting body fat percentages where the lipolytic stimulus needs more time to produce measurable results.

Off-period: Minimum 4 weeks between cycles. Many practitioners recommend 6-8 weeks off to fully reset receptor sensitivity. During the off-period, fat loss can be maintained through the diet and exercise habits established during the active cycle.

Repeat cycles: 2-3 cycles per year is a reasonable frequency. Each subsequent cycle should be evaluated based on whether meaningful additional fat loss is needed — there is no benefit to cycling AOD-9604 if body composition goals have been met.

Combination options

AOD-9604 combines well with several other interventions, both peptide and non-peptide. The key principle is to select combinations that attack fat loss through complementary mechanisms rather than redundant ones.

AOD-9604 + Frag 176-191: These are closely related compounds (AOD-9604 is a modified version of HGH Fragment 176-191). Combining them is generally unnecessary — choose one or the other. AOD-9604 is preferred due to its improved stability and slightly better-characterized mechanism.

AOD-9604 + Tesamorelin: Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that increases endogenous GH secretion. This combination provides direct lipolytic stimulation (AOD-9604) plus increased endogenous GH pulsatility (tesamorelin) for broader metabolic support. Tesamorelin is particularly effective for visceral fat reduction and has FDA approval for HIV-associated lipodystrophy. This is a strong combination for individuals targeting both subcutaneous and visceral fat.

AOD-9604 + CJC-1295/Ipamorelin: This growth hormone secretagogue combination enhances GH release, supporting fat oxidation, lean mass preservation, and recovery. Running CJC-1295/Ipamorelin at bedtime and AOD-9604 in the fasted morning creates two distinct windows of lipolytic activity without pharmacological conflict.

AOD-9604 + Caloric deficit: This is the foundational combination. AOD-9604 enhances fat oxidation, but it does not override thermodynamics. A moderate caloric deficit (300-500 calories below maintenance) provides the energy balance necessary for net fat loss while AOD-9604 preferentially directs that deficit toward fat stores rather than lean tissue.

AOD-9604 + Resistance training: Resistance training preserves lean mass during a caloric deficit and increases the metabolic rate. The combination with AOD-9604 supports body recomposition — simultaneous fat loss and lean mass maintenance — rather than simple weight loss where muscle and fat are lost together.

AOD-9604 + Cardiovascular exercise: Moderate-intensity cardiovascular exercise (walking, cycling, swimming at 60-70% max heart rate) performed in the fasted window after AOD-9604 injection may enhance acute fat oxidation. This is a common practice, though controlled data specifically for AOD-9604 combined with fasted cardio are limited.

Monitoring

AOD-9604 has a favorable safety profile and does not require the intensive monitoring associated with GH therapy or GLP-1 agonists. However, basic monitoring ensures the protocol is working and catches any unexpected effects.

Before starting (baseline):

Body weight, waist circumference, and body composition measurement (DEXA scan is the gold standard; bioimpedance is acceptable for tracking trends)
Fasting glucose and fasting insulin (to confirm AOD-9604 is not needed — if fasting insulin is markedly elevated, addressing insulin resistance should be the priority before using a lipolytic peptide)
Lipid panel (total cholesterol, LDL, HDL, triglycerides)
Progress photographs (front, side, back) under consistent lighting conditions

During the cycle (every 4 weeks):

Body weight and waist circumference
Progress photographs
Subjective assessment of energy, appetite, and sleep quality

End of cycle:

Repeat all baseline measurements
Body composition scan to quantify changes in fat mass and lean mass separately
Lipid panel to assess metabolic improvement

What you should NOT expect to change: Unlike GH or GH secretagogue protocols, AOD-9604 does not meaningfully alter IGF-1 levels, fasting glucose (it may modestly improve it), or any standard hormone panel. If a blood test shows elevated IGF-1 during an AOD-9604-only protocol, the compound is not pure AOD-9604.

Side effects and management

AOD-9604 has one of the most benign side effect profiles of any peptide used for body composition. This is by design — the compound was specifically engineered to remove the side effects of full GH while retaining lipolytic activity.

Injection site reactions: Mild redness, slight swelling, or temporary discomfort at the injection site. These are common to all subcutaneous injections and are not specific to AOD-9604. Rotate injection sites to minimize. If reactions are persistent, verify the bacteriostatic water concentration (0.9% benzyl alcohol is standard).

Transient headache: Reported by a small percentage of users, typically during the first few days. Usually resolves without intervention. Adequate hydration and ensuring the peptide is administered with sufficient water intake (250-500 mL at the time of injection) can help.

Mild GI discomfort: Rare, but some users report mild nausea or stomach discomfort if they eat too soon after injection. Adhering to the 30-60 minute fasting window after injection typically resolves this.

What you should NOT experience: AOD-9604 should not cause water retention, joint pain, carpal tunnel symptoms, blood sugar elevation, or any of the classic GH side effects. If these occur, the product may contain full-length GH or other contaminants. Discontinue and source from a verified provider.

Hypoglycemia risk: AOD-9604 does not lower blood sugar in the way that insulin or GLP-1 agonists do. However, combining it with a fasted state, vigorous exercise, and a caloric deficit could theoretically produce symptoms of low blood sugar in sensitive individuals. If lightheadedness or shakiness occurs during fasted morning exercise after AOD-9604 injection, break the fast before exercising and administer the injection separately from the exercise window.

FAQ

How quickly will I see results with AOD-9604?

Most users begin to notice changes in body composition at 3-4 weeks, with more substantial results visible at 6-8 weeks. The initial 2-3 weeks are an adaptation period where the lipolytic mechanisms are being activated but the cumulative fat loss is not yet visually apparent. Weight scale changes may be slower than expected because AOD-9604 supports lean mass preservation — you may be losing fat while maintaining muscle, which limits the total weight change but improves how you look and feel. Waist circumference and progress photographs are more informative than the scale during an AOD-9604 cycle.

Can I use AOD-9604 without dieting?

Technically yes, but results will be significantly diminished. AOD-9604 enhances the rate of fat oxidation, but if caloric intake exceeds expenditure, the fat that is mobilized will simply be re-stored. Think of AOD-9604 as an accelerant, not a replacement, for the caloric deficit required for fat loss. Users who combine AOD-9604 with even a modest dietary adjustment (300-500 calorie deficit) consistently report better outcomes than those who rely on the peptide alone.

Is AOD-9604 the same as HGH Fragment 176-191?

They are related but not identical. HGH Fragment 176-191 is the unmodified C-terminal fragment of human growth hormone (amino acids 176-191). AOD-9604 is a modified version of that fragment with a tyrosine amino acid added, which improves stability and lipolytic activity. In practice, both compounds target the same mechanism, but AOD-9604 is generally preferred due to its better stability profile and more extensive clinical investigation.

Does AOD-9604 affect growth hormone levels or IGF-1?

No. This is one of AOD-9604's primary advantages over full GH therapy or GH secretagogues. AOD-9604 does not increase circulating GH, does not elevate IGF-1, and does not affect pituitary function. It acts directly on adipose tissue through the beta-3 adrenergic pathway. This means it does not carry the risks associated with supraphysiologic GH — no joint pain, no water retention, no insulin resistance, no acromegaly risk.

Can women use AOD-9604?

Yes. AOD-9604 has no sex-specific contraindications. The dosing recommendations are the same for men and women. Women who are pregnant, planning pregnancy, or breastfeeding should not use AOD-9604 or any peptide protocol due to the absence of safety data in these populations.

What happens when I stop AOD-9604?

Fat loss will slow to the rate determined by your diet and exercise alone. There is no "rebound" effect — AOD-9604 does not suppress any endogenous hormone or metabolic pathway that would cause accelerated fat gain upon discontinuation. The body composition improvements achieved during the cycle are maintained as long as the dietary and exercise habits that supported them are continued.